News iBio, Inc.

Equities

IBIO

US4510337086

Real-time Estimate Cboe BZX Other stock markets 16:21:03 29/04/2024 BST			5-day change	1st Jan Change
1.765 ^USD	+0.28%		-1.12%	+28.47%

04-01	IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors	CI
03-28	Top Premarket Gainers	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors	03-31	CI
Top Premarket Gainers	03-28	MT
Top Midday Gainers	03-27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	03-27	MT
Transcript : IBio, Inc. - Special Call	03-27
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings	03-27	MT
Top Premarket Gainers	03-27	MT
IBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases	03-27	AQ
IBio, Inc. and AstralBio, Inc. Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases	03-27	CI
IBio Announces $15.0 Million Private Placement	03-27	AQ
IBio, Inc. announced that it has received $14 million in funding	03-25	CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	02-26	DJ
IBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka	02-26	AQ
Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc..	02-24	CI
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-09	CI
IBio Announces Participation in 23rd Annual PepTalk Conference	01-16	AQ
IBio Amends and Extends Maturity of Credit Agreement	12-26	AQ
Top Midday Decliners	12-05	MT
IBio, Inc. Announces Pricing of $4.5 Million Public Offering	12-05	AQ
Top Premarket Decliners	12-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News iBio, Inc.

Equities

IBIO

US4510337086

Summary

Filters